SBIR/STTR Research Award
Novel Targeted Cytokine for Chronic Kidney Disease
Award amount
$224,243Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Panorama Research Incorporated
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LYVHC3ARFRJ7
- Solicitation number
- PA13-234
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): Novel Targeted Cytokine for Chronic Kidney Disease End stage renal disease (ESRD) affects gt485,000 Americans, including over 341,000 hemodialysis patients with an estimated 90,000 new cases per year. The annual cost oftreating Americans suffering from some form of kidney failure is about 23 billion. Progression of kidney disease is characterized by a persistent inflammatory response that causes irreversible renal glomerulosclerosis and tubulointerstitial fibrosis eventually leading to ESRD (reviewed in Kanamaru, 2008). Bone morphogenetic protein 7 (BMP7) plays an important role in kidney homeostasis through its interaction with activin-like-kinase receptors 2,3, 6 (alk2, alk3, alk6) an BMPR2. Treatment with or ectopicexpression of BMP7 in chronic kidney disease (CKD) blocks apoptosis, reduces inflammation, reverses the epithelial to mesenchymal transition (EMT) and fibrosis, inducing kidney regeneration [1] [2]. Recombinant BMP7 (rBMP7) would be a promising therape
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Therapy for Sarcopenia
- Novel therapy to prevent alveolar bone loss in severe periodontitis
- Novel therapy for arthrofibrosis
- Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
- Monoclonal antibody for autoimmune disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
149 SBIR/STTR records share this UEI (1990–2025). Reported award amounts total $35,373,004. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Agriculture, National Science Foundation